COMPANY CONFIDENTIAL
PREVENZIONE DELLE INFEZIONI ATTRAVERSO L’USO DEL SISTEMA DI DISINFEZIONE 99T
NO TOXICIDAD DEL DEPÓSITO DE PLATA– bibliografía de respaldo
* Dottor Gusmeri Walter – CFG sas – Milán - Italia – Ref: Rdp.A018
Resumen:Declaración de no toxicidad de la plata, respaldada por una amplia bibliografía detallada.
1. INTRODUCCIÓN
Teniendo en cuenta que la concentración de iones de
plata depositada en las superficies de los ambientes
tratados con sistema 99.99TM, es muy baja y no está
previsto un contacto directo por parte de las personas
que transitan y/o residen en los ambientes tratados con
el sistema, se puede afirmar con gran tranquilidad que
los depósitos de plata son seguros y sin efectos adversos.
Para comprobar cuanto afirmado, ha sido efectuada una
investigación cuidadosa en literatura científica,
encontrando una completa correspondencia a lo
señalado.
2. BIBLIOGRAFÍADERESPALDO
Referencias:
1. Poon and Burd (2004) Burns; 140-147.
2. Hidalgo (1998) Skin Pharmacol; 140-151.
3. Lansdown A. (2004) J. Wound Care; 13 (4) 131-136.
4. Innes et al (2001) Burns; 621-627.
5. Demling&DeSanti (2002) Burns; 28: 264-266.
6. Chooi et al (2005) Poster to be presented at ETRS.
7. Maitre et al (2002) Ann. Dermatol. Venereol.; 129:
217-220.
8. Sue et al (2001) Am. J. Kid. Dis.; 37 (5): 1058-1051.
9. Clement International Corporation (1990)
„Toxicological Profile for Silver‟ prepared for Agency for
Toxic Substances and Disease Registry; U.S. Public Health
Service.
10. A.Lansdown “Clinical observations
neurotoxicity of silver”.
11. Vermeulen H et al, “Topical silver for treating
infected wounds (review)” the Cochrane Collaboration
2007, pag.3.
12. Okan D, Woo K, SibbaldRG.“So what if you are blue?
Oral colloidal silver and argyria are out: safe dressings
are in.” Adv Skin Wound Care. 2007 Jun;20(6):326-30.
1
99T_Y_211212_dichiarazione-non-tossicità-Ag_ita_1.0
13. Marshall JP 2nd, Schneider RP.“Systemicargyria
secondary to topical silver nitrate.”Arch Dermatol. 1977
Aug;113(8):1077-9.
14. Sue YM, Lee JY, Wang MC, Lin TK, Sung JM, Huang
JJ.“Generalizedargyria in two chronic hemodialysis
patients.” Am J Kidney Dis. 2001 May;37(5):1048-51.
15. Van Garsse L, VersieckJ.“Generalargyria caused by
administration of tobacco-withdrawal tablets containing
silver acetate”NedTijdschrGeneeskd. 1995 Dec
23;139(51):2658-61. Dutch.
16. Van de Voorde K, Nijsten T, Schelfhout K, Moorkens
G, Lambert J.“Long-term use of silver containing nose-
drops resulting in systemic argyria.” ActaClin Belg. 2005
Jan-Feb;60(1):33-5.
17. Nielsen IO, KjaerboE.“Generalizedargyria due to the
use of eyedrops containing silver nitrate” UgeskrLaeger.
1989 Jan 2;151(1):33-4. Danish.
18. Aaseth J, Olsen A, Halse J, HovigT.Argyria-tissue
deposition of silver as selenide.”Scand J Clin Lab Invest.
1981 May;41(3):247-51.
19. Stadie, V., Marsch WC. “Argyria, an almost-forgotten
dyschromia“ J.DtschDermatolGes. 2004, feb;2(2): 119-22
20. Lee SM, Lee SH: “Generalyzedargyria after habitual
use of AgNO3” J.
21. Wadhera A, Fung M. Systemic argyria associated with
ingestion of colloidal silver Dermatol Online J
2005;11(1):12.
22. Nancy Tomaselli Dorothy Doughty MN”The Role of
on the Topical Silver Preparations in Wound Healing” Journal of
Wound, Ostomy and Continence Nursing July/August
2006 Volume 33 Number 4 Pages 367 – 378.
23. Wolfgang Vanscheidt et al.,” Safety Evaluation of a
New Ionic Silver Dressing in the Management of Chronic
Ulcers” Wounds - ISSN: 1044-7946 - Volume 15 - Issue 11
- November 2003 - Pages: 371 – 378.
24. Hermans, M.H. “Silver containing dressings and the
need of evidence”, AJN dec.2006 vol.106 n°12 pag.62.
25. Robert E. Burrell, PhD “A Scientific Perspective on the
Use of Topical Silver Preparations” Ostomy/Wound
99 Technologies S.A.
Via al Chioso, 8 - 6900 Lugano – Svizzera
info@99technologies.ch
 COMPANY CONFIDENTIAL

PREVENZIONE DELLE INFEZIONI ATTRAVERSO L’USO DEL SISTEMA DI DISINFEZIONE 99T

Management - ISSN: 0889-5899 - Volume 49 - Issue 5A - May 2003 - Pages:19 – 24.

26. Walker M. Cochrane CA et al(ConvaTec Wound study of systemic silver absorption” b u rns 33 (2007) 979
Therapeutics)., “Silver deposition and tissue staining – 85.
associated with wound dressings containing silver”
31. Coombs CJ, Wan AT, Masterton JP, Conyers RAJ,
OWM, 2006 jan;52(1):42-4, 46-50.
Pederson J, Chia YT. Do burn patients have a silver lining?
27. Supp A. et al. “Evaluation of ccytotoxicity and Burns 1992;18:179–84.
antimicrobial activity of Argentonanocristallino Burn
32. Li X et al (1997) Silver-resistant mutants of
dressing for management of microbial contamination in
Escherichia coli display active efflux of Ag+ and are
cultured skin substitutes grafted to athymicmice
deficient in porins. Journal of Bacteriology. 179, 19,
“J.ofBurn Care and rehab. Vol.26 n°3.
6127-6132.
28. Rustogi R. Mill J. Fraser J.F. Kimble R.M. “The use of
33. Caroline Dowsett DN, RGN, MSc,” The use of silver-
Argentonanocristallino in neonatal burns” Burns 31
based dressings in wound care. Nursing Standard.19, 7,
(2005) 878-882.
56- 60.
29. Gary Sibbald et al.: ”Bacteriology, inflammation, and
34. Leaper DJ. “Silver dressings: their role in wound
healing: a study of nanocrystalline silver dressings in
management”. Int Wound J 2006;3:282–294.
chronic venous leg ulcers” Advances in skin and wound
care – october 2007 pag 549-558. 35. Chopra J. “The increasing use of silver-based products
as antimicrobial agents: a useful development or a cause
30. EvangeliaVlachou, Elizabeth Chipp, Elizabeth Shale,
for concern? Journal of Antimicrobial Chemotherapy
Yvonne T. Wilson, Remo Papini, Naiem S. Moiemen: The
(2007) 59, 587–590.
safety of nanocrystalline silver dressings on burns:A

DOCUMENTO TRADUCIDO POR LA

CÁMARA DE COMERCIO ITALIANA DEL
PERÚ

99 Technologies S.A.
Via al Chioso, 8 - 6900 Lugano – Svizzera
info@99technologies.ch
2
99T_Y_211212_dichiarazione-non-tossicità-Ag_ita_1.0